The role of circulating lipoprotein lipase and adiponectin on the particle size of remnant lipoproteins in patients with diabetes mellitus and metabolic syndrome

Clinica Chimica Acta

Volumn 440, Issue , 2015, Pages 123-132

  Shirakawa, Takashi ^a,c   Nakajima, Katsuyuki ^a,b,d   Yatsuzuka, Shin ichi ^a   Shimomura, Younosuke ^a   Kobayashi, Junji ^d   Machida, Tetsuo ^c   Sumino, Hiroyuki ^c   Murakami, Masami ^c  

^a Hidaka Hospital   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adiponectin; Diabetes mellitus (DM); Lipoprotein lipase (LPL); Metabolic syndrome (MetS); Remnant lipoproteins (RLPs); RLP TG RLP C ratio

Indexed keywords

ADIPONECTIN; CHOLESTEROL; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REMNANT LIPOPROTEIN; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; ADIPOQ PROTEIN, HUMAN; LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN TRIGLYCERIDE;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; FATTY LIVER; FEMALE; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PARTICLE SIZE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; CASE CONTROL STUDY; DIET RESTRICTION; NON INSULIN DEPENDENT DIABETES MELLITUS; STATISTICAL MODEL;

ADIPONECTIN; ADULT; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FASTING; FATTY LIVER; FEMALE; HUMANS; LINEAR MODELS; LIPASE; LIPOPROTEIN LIPASE; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PARTICLE SIZE; TRIGLYCERIDES;

EID: 84911864042     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.10.029     Document Type: Article

References (52)

1. Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
2. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 1999, 246:341-355.
3. Nakajima K., Nakano T., Tokita Y., et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clin Chim Acta 2011, 412:1306-1318.
4. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation 1979, 60:473-450.
5. Gastaldelli A., Kozakova M., Højlund K., et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009, 49:1537-1544.
6. Nakajima K., Saito T., Tamura A., et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti A-1 immunoaffinity mixed gels. Clin Chim Acta 1993, 223:53-71.
7. Okazaki M., Usui S., Tada N., Nakano T., Nakajima K. Relation between RLP-triglyceride to RLP-cholesterol ratio and particle size distribution in cholesterol profiles by HPLC. Clin Chim Acta 2000, 296:135-149.
8. Rip J., Nierman M.C., Wareham N.J., et al. Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2006, 26:637-642.
9. Hitsumoto T., Takahashi M., Iizuka T., Shirai K. Relationship between two AMI risk factors: low serum lipoprotein lipase mass and hypoadiponectinemia. J Atheroscler Thromb 2011, 18:148-156.
10. Havel R.J., Kane J.P., Kashyap M.L. Interchange of apolipoproteins between chylomicrons and high-density lipoproteins during alimentary lipemia in man. J Clin Invest 1973, 52:32-38.
11. Brunzell J.D., Deeb S.S. Familial lipoprotein lipase deficiency, apo C-II deficiency and hepatic lipase deficiency. The metabolic and molecular basis of inherited disease 2001, 2789-2816. Mc Graw-Hill Inc., New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
12. Beisiegel U., Weber W., Bengtason-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci U S A 1991, 88:8342-8346.
13. Chappell D.A., Fry G.L., Waknitz M.A., Iverius P.-H., Williams S.E., Strickland D.K. The low density lipoprotein receptor-related protein/a2-macroglobulin receptor binds and mediates catabolism of bovine milk lipoprotein lipase. J Biol Chem 1992, 267:25764-25767.
14. Eisenberg F., Sehayek E., Olivecrona T., Vlodavsky I. Lipoprotein lipase enhances binding of lipoproteins to heparan sulphate on cell surfaces and extracellular matrix. J Clin Invest 1992, 90:2013-2021.
15. Chappell D.A., Fry G.L., Waknitz M.A., Muhonen L.E., Pladet M.W. Lipoprotein lipase induces catabolism of normal triglyceride-rich lipoproteins via the low density lipoprotein receptor-related protein/a2-macroglobulin in vitro. A process facilitated by cell-surface proteoglycans. J Biol Chem 1993, 268:14168-14175.
16. Nylcjaer A., Bengtason-Olivecrona G., Lookene A., et al. The a2-macroglobulin receptor/low density lipoprotein receptor-related protein binds lipoprotein lipase and beta-migrating very low density lipoprotein associated with the lipase. J Biol Chem 1993, 268:15048-15055.
17. Merkel M., Kako Y., Radner H., et al. Catalytically inactive lipoprotein lipase expression in muscle of transgenic mice increases very low density lipoprotein uptake: direct evidence that lipoprotein lipase bridging occurs in vivo. Proc Natl Acad Sci U S A 1998, 95:13841-13846.
18. Endo K., Miyashita Y., Saiki A., et al. Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. J Atheroscler Thromb 2004, 11:341-347.
19. Kinoshita T., Shirai K., Itoh M. The level of pre-heparin serum lipoprotein lipase mass at different stages of pregnancy. Clin Chim Acta 2003, 337:153-156.
20. Kobayashi J., Saito K., Fukamachi I., et al. Pre-heparin plasma lipoprotein lipase mass: its correlation with intra-abdominal visceral fat accumulation. Horm Metab Res 2001, 33:412-416.
21. Miyashita Y., Shirai K., Itoh Y., et al. Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res Clin Pract 2002, 56:181-187.
22. Totsuka M., Miyashita Y., Ito Y., et al. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration. Atherosclerosis 2000, 153:175-179.
23. Hitsumoto T., Ohsawa H., Uchi T., et al. Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis 2000, 153:391-396.
24. Hitsumoto T., Yoshinaga K., Aoyagi K., et al. Association between preheparin serum lipoprotein lipase mass and acute myocardial infarction in Japanese men. J Atheroscler Thromb 2002, 9:163-169.
25. Saiki A., Oyama T., Endo K., et al. Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract 2007, 76:93-101.
26. Hirano T., Nishioka F., Murakami T. Measurement of the serum lipoprotein lipase concentration is useful for studying triglyceride metabolism: comparison with postheparin plasma. Metabolism 2004, 53:526-531.
27. Shirakawa T., Nakajima K., Shimomura Y., et al. Comparison of the effect of post-heparin and pre-heparin lipoprotein lipase and hepatic triglyceride lipase on remnant lipoprotein metabolism. Clin Chim Acta 2014, [in press].
28. Chan D.C., Watts G.F., Barrett P.H., O'neill F.H., Redgrave T.G. Relationships between cholesterol homeostasis and triglyceride-rich lipoprotein remnant metabolism in the metabolic syndrome. Clin Sci 2003, 104:383-388.
29. Chan D.C., Watts G.F., Ng T.W., et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem 2005, 51:578-585.
30. Yatsuzuka S., Shimomura Y., Akuzawa M., et al. Plasma adiponectin is a more specific marker of fatty liver than a marker of metabolic syndrome in Japanese men. Ann Clin Biochem 2013, 51:68-79.
31. Teramoto T., Sasaki J., Ueshima H., et al. Metabolic syndrome. J Atheroscler Thromb 2008, 15:1-5.
32. Miyashita K., Kobayashi J., Imamura S., et al. A new enzyme-linked immunosorbent assay system for human hepatic triglyceride lipase. Clin Chim Acta 2013, 424:201-206.
33. Kasama T., Yoshino G., Iwatani I. Increased cholesterol concentration in intermediate density lipoprotein fraction of normolipidemic non-insulin-dependent diabetics. Atherosclerosis 1987 Feb, 63(2-3):263-266.
34. Adiels M., Olofsson S.O., Taskinen M.R., Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1225-1236.
35. Lucero D., Zago V., López G.H., et al. Predominance of large VLDL particles in metabolic syndrome, detected by size exclusion liquid chromatography. Clin Biochem 2012, 45:293-297.
36. Phillips N.R., Waters D., Havel R. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993, 88:2762-2770.
37. Karpe F., Steiner G., Uffelman K., Olivecrona T., Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994, 106:83-97.
38. Hamsten A., Silveira A., Boquist S., et al. The apolipoprotein CI content of triglyceride-rich lipoproteins independently predicts early atherosclerosis in healthy middle-aged men. J Am Coll Cardiol Apr 5 2005, 45:1013-1017.
39. Lewis G.F. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 1997, 8:146-153.
40. Olivecrona T., Bengtsson-Olivecrona G. Lipoprotein lipase and hepatic lipase. Curr Opin Lipidol 1990, 1:222-230.
41. Eckel R.H. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic disorders. N Engl J Med 1989, 320:1060-1068.
42. Watson T.D., Tan C.E., McConnell M., et al. Measurement and physiological significance of lipoprotein and hepatic lipase activities in preheparin plasma. Clin Chem 1995, 41:405-412.
43. Bengtsson-Olivecrona G., Olivecrona T. Assay of lipoprotein lipase and hepatic lipase. Lipoprotein analysis. A practical approach 1992, 169-185. Oxford University Press, Oxford. R.E. Skinner, C.A. Concverse (Eds.).
44. Eckel R.H., Goldberg I.J., Steiner L., Yost T.J., Paterniti J.R. Plasma lipolytic activity. Relationship to postheparin lipolytic activity and evidence for metabolic regulation. Diabetes 1988, 37:610-615.
45. Glasser D.S., Yost T.J., Eckel R.H. Preheparin lipoprotein lipolytic activities: relationship to plasma lipoproteins and postheparin lipolytic activities. J Lipid Res 1992, 33:209-214.
46. Karpe F., Olivecrona T., Walidius G., Hamsten A. Lipoprotein lipase in plasma after an oral fat load: relation to free fatty acids. J Lipid Res 1992, 33:975-984.
47. Vilella E., Joven J., Fernández M., et al. Lipoprotein lipase in human plasma is mainly inactive and associated with cholesterol-rich lipoproteins. J Lipid Res 1993, 34:1555-1564.
48. Weiss R., Otvos J.D., Flyvbjerg A., et al. Adiponectin and lipoprotein particle size. Diabetes Care 2009, 32:1317-1319.
49. Vergès B. Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. Atherosclerosis 2010, 211:353-360.
50. Ng T.W., Watts G.F., Farvid M.S., Chan D.C., Barrett P.H. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics?. Diabetes 2005, 54:795-802.
51. Maruyoshi H., Kojima S., Funahashi T., et al. Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina. Thromb Haemost 2004, 91:1026-1030.
52. Tian C., Ye X., Zhang R., et al. Green tea polyphenols reduced fat deposits in high fat-fed rats via erk1/2-PPARγ-adiponectin pathway. PLoS One 2013, 8(1):e53796.